Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.44 |
| ▸ | TDO2 | P48775 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24740169 | 0.78 | IDO1 (0.48) | IDO1TDO2KMT2AGSK3BBRPF1 | |
| SCHEMBL24740261 | 0.78 | IDO1 (0.48) | IDO1TDO2KMT2AGSK3BBRPF1 | |
| SCHEMBL7770262 | 0.75 | — | — | |
| SCHEMBL23836089 | 0.74 | IDO1 (0.46) | IDO1TDO2KMT2AGSK3BBRPF1 | |
| SCHEMBL7310972 | 0.74 | IDO1 (0.46) | IDO1TDO2KMT2AGSK3BBRPF1 | |
| SCHEMBL9278082 | 0.72 | ALDH1A1 (0.38) | IDO1TDO2MAPTALDH1A1TDP1 | |
| SCHEMBL12520453 | 0.71 | IDO1 (0.44) | IDO1TDO2KMT2AGSK3BBRPF1 | |
| SCHEMBL6243496 | 0.70 | IDO1 (0.46) | IDO1TDO2GSK3BBRPF1CREBBP | |
| SCHEMBL20416267 | 0.70 | IDO1 (0.43) | IDO1TDO2KMT2AGSK3BBRPF1 | |
| SCHEMBL6682761 | 0.70 | HTR2A (0.39) | KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362067-B2 | 3-aminoalkyl-1,3-dihydro-2H-indol-2-one derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-29 | — | — | US | disclosed |
| US-8362067-B2 | 3-aminoalkyl-1,3-dihydro-2H-indol-2-one derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-29 | — | — | US | disclosed |
| US-8362067-B2 | 3-aminoalkyl-1,3-dihydro-2H-indol-2-one derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-29 | — | — | US | disclosed |
| EP-2265582-B1 | NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF. | SANOFI SA (FR) | 2012-01-04 | — | — | EP | disclosed |
| CN-102015642-A | Novel 3-aminoalkyl-1, 3-dihydro-2H-indol-2-one derivatives, preparation method and therapeutic use thereof | SANOFI AVENTIS | 2011-04-13 | — | — | CN | disclosed |
| US-20110059955-A1 | NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | disclosed |
| US-20110059955-A1 | NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | disclosed |
| EP-2265582-A1 | NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF. | Sanofi-Aventis (FR) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009115685-A1 | NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF. | SANOFI-AVENTIS (FR) | 2009-09-24 | — | — | WO | disclosed |
| US-4663482-A | Intermediates for preparing 7-(2-aminoethyl)-1,3-benzthia- or oxa- zol-2(3H)-ones | SMITHKLINE BECKMAN CORPORATION (US) | 1987-05-05 | — | — | US | disclosed |
| EP-0174811-A2 | 7-(2-aminoethyl)-1,3-Benzthia- or oxa- zol-2(3H) -ones | SMITHKLINE BECKMAN CORPORATION (US) | 1986-03-19 | — | — | EP | disclosed |
| US-4554284-A | 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones | SMITHKLINE BECKMAN CORPORATION (US) | 1985-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059955-A1 | NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | AVPR1B, AVPR1A, AVPR2 | IDO1 160/4885TDO2 1032/4885KMT2A 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.